Tremeau Pharmaceuticals Inc. is pleased to announce the expansion of its leadership team. Key additions to the team include Judith Boice, PhD as Chief Development Officer and Ray Skwierczynski, PhD as Head of Technical Operations.

Dr. Boice joins Tremeau from Alexion Pharmaceuticals, where she was Vice President and Global Development Team Leader, and Head of Medical Communications. Prior to Alexion, Dr. Boice spent 16 years at Merck Research Laboratories, where she was a Product Development Team Leader and also was responsible for executive oversight for numerous clinical trials for the COX-2 inhibitors VIOXX (rofecoxib) and ARCOXIA (etoricoxib).

Bradford Sippy, CEO, noted that “Judith’s extensive experience and expertise  in clinical development make her the ideal person to lead development at Tremeau. It would be difficult to find a clinical development expert with more knowledge about our assets, or a former colleague whom I have more respect for, than Dr. Boice.”

Dr. Skwierczynski brings extensive pharmaceutical technical operations experience to Tremeau, including senior roles at CoLucid (acquired by Eli Lilly in 2017) and Takeda. Dr. Skwierczynski, a recognized pharmaceutical industry leader in the field of Chemistry, Manufacturing, and Controls (CMC), serves as a member of the Expert Committee for the United States Pharmacopeia.

Mr. Sippy went on to note that “under Ray’s guidance, Tremeau has made great strides in our CMC development activities. With Ray on board, Tremeau will pursue additional formulations for our portfolio of products, while we simultaneously scale-up our manufacturing capacity for our current oral formulations in development.”

To learn more about Tremeau’s expanded leadership team, please click here.